Michael Guerrera
Pediatric Hematology-Oncology · Washington, DCNPI 1548354723
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sanofi at 33.2% of the total. Reporting peaked in 2019 at $124,551 and has fallen 62.6% since, to $46,559 in 2025. Among pediatric hematology-oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $1440.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$104K
- Bioverativ Therapeutics Inc.$69K
- Novo Nordisk$38K
- Biomarin Pharmaceutical Inc.$21K
- Shire North American Group Inc$20K
- Sanofi-aventis U.S. LLC$16K
- plus $47K from 8 others
Across 93 payments — averaging $1253.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Swedish Orphan Biovitrum AB$88K
- Bioverativ Therapeutics Inc.$16K
- Sanofi US Services Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- HEMA Biologics, LLC$2K
- Novo Nordisk AS$500
What the payments were for
- Consulting fees$107,32934%
- Speaking & faculty fees$174,19355%
- Travel & lodging$27,2269%
- Food & beverage$5,2022%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 58 | $104,128 |
| Bioverativ Therapeutics Inc. | 44 | $68,645 |
| Novo Nordisk | 30 | $37,915 |
| Biomarin Pharmaceutical Inc. | 16 | $20,510 |
| Shire North American Group Inc | 22 | $19,539 |
| Sanofi-aventis U.S. LLC | 9 | $16,308 |
| Genentech USA, Inc. | 15 | $16,111 |
| Sanofi US Services Inc. | 1 | $14,718 |
| Bayer | 12 | $10,217 |
| Kedrion Biopharma Inc. | 2 | $3,200 |
| HEMA Biologics, LLC | 6 | $2,515 |
| Octapharma USA, Inc. | 1 | $84 |
| Pfizer | 1 | $47 |
| Genentech, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$313,962 in reported general payments places this provider in the 95th percentile of 46 pediatric hematology-oncology providers in District of Columbia.
See all pediatric hematology-oncology providers in District of Columbia →
Other pediatric hematology-oncology in Washington
- Caterina MinnitiWashington$478K
- Deepika DarbariWashington$97K
- Naomi LubanWashington$27K
- Holly MeanyWashington$23K
- Anne AngiolilloWashington$22K
- Eugene HwangWashington$21K
- Gary KupferWashington$21K
- Catherine BollardWashington$15K
- James TaylorWashington$14K
- Suvankar MajumdarWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.